Business Blockbuster - Helpng business to be more visible on Google

Business Daily Media


.

Uni-Bio Science Joins Forces with WMU NERC and Ouhai District Government to Build Growth Factor Innovation Ecosystem and Accelerate Regenerative Medicine Strategy Layout

HONG KONG SAR - EQS Newswire - 30 December 2025 - Uni-Bio Science Group Limited ("Uni-Bio Science Group", "Uni-Bio" or "the Group") is pleased to announce the official signing of a tripartite strategic cooperation agreement in Wenzhou, Zhejiang, with the National Engineering Research Center for Cell Growth Factor Drugs and Protein Formulations of Wenzhou Medical University ("WMU NERC") and the People's Government of Ouhai District, Wenzhou.

The parties also explored the subsequent co-establishment of the "Uni-Bio - WMU Joint Innovation Laboratory for Translational Medicine." This collaboration marks a key step for Uni-Bio in deeply integrating with a national-level research platform and a regional industrial ecosystem. Through a synergistic "government-university-enterprise" model, the three parties will focus on the core regenerative medicine field of growth factors to establish an end-to-end innovation system spanning basic research, clinical translation, and industrial application. This represents a milestone for the Group in consolidating its R&D pipeline and accelerating its strategic execution.

Strategic cooperation signing ceremony group photo
Strategic cooperation signing ceremony group photo

Focusing on Growth Factor Frontiers, Unleashing "1+1>2" Clinical and Market Potential

Growth factors are key signaling molecules that regulate cell proliferation, migration, and tissue repair, representing some of the most transformative bioactive substances in regenerative medicine. Both EGF (Epidermal Growth Factor) and FGF (Fibroblast Growth Factor) have demonstrated significant efficacy across major indications, including wound healing, ophthalmic diseases, and metabolic disorders, underscoring their substantial market potential.

Uni-Bio possesses deep expertise in the EGF field, with its flagship products GeneTime® and GeneSoft® achieving large-scale production and nationwide commercial coverage. Concurrently, under the leadership of Academician Li Xiaokun, the WMU NERC has been a global pioneer in FGF drug R&D, having successfully translated several Class I New Drugs - including Recombinant Human Basic Fibroblast Growth Factor - and has accumulated substantial clinical data and authoritative expert consensus in trauma and metabolic diseases.

Building on this foundation, the three parties will initiate collaborative research on combined EGF/FGF therapies for key areas, including burns, dermatology, and ophthalmology. The goal is to unlock powerful therapeutic synergies, develop superior combination products and advance delivery systems, set new treatment benchmarks, and establish a leadership position in shaping this multi-billion Yuan sector.

Empowered by Academician Leadership & Platform, Creating a Fast Track from R&D to Production

The WMU NERC is an independent legal entity established by Wenzhou Medical University based on the national-level platform, the National Engineering Research Center for Cell Growth Factor Drugs and Protein Preparations. It undertakes downstream functions including engineering technology research and development, transformation of scientific and technological achievements, and technical services. In synergistic collaboration with the National Key Laboratory for Macromolecular Drugs and Large-Scale Preparation, which focuses on upstream basic research, the Center has built a next-generation growth factor drug pipeline targeting multiple systems such as metabolism and dermatology. Through the ongoing research of Academician Li Xiaokun's team, the Center has achieved internationally leading breakthroughs in key technologies, including long-acting Modification, targeted delivery, and aerosol inhalation.

The planned "Uni-Bio – WMU Joint Innovation Laboratory for Translational Medicine" will conduct in-depth research into the synergistic mechanisms of Epidermal Growth Factor (EGF) and Fibroblast Growth Factor (FGF) in regulating metabolic homeostasis, improving insulin sensitivity, and promoting tissue repair. It aims to develop novel compound formulations and drug delivery systems targeting conditions such as endocrine diseases represented by non-alcoholic steatohepatitis (NASH), respiratory diseases represented by asthma, as well as bone tissue repair. These diseases affect a large global patient population, yet there remains a significant unmet clinical need for innovative therapies. Through this collaboration, it is expected to address treatment gaps in multiple specific indications, further unlocking clinical and commercial value in the broad chronic disease market.

The "Government-University-Enterprise " Trinity, Systematically Strengthening Full-Chain Capabilities

This collaboration extends beyond technological synergy to ecosystem co-development. The People's Government of Ouhai District, Wenzhou, is a key facilitator and supporter of this strategic cooperation, committed to building a first-class biomedical industry ecosystem. Its core platform, the "China Gene Valley," will provide comprehensive spatial support and specialized policy assistance for the cooperative projects across all stages – from R&D and pilot-scale testing to industrialization.

For Uni-Bio, this tripartite cooperation delivers threefold empowerment:

  • R&D Front: Direct access to the National Engineering Research Center's source innovation and core technologies, elevating the starting point of R&D.
  • Clinical Front: Collaboration with Wenzhou Medical University's affiliated hospital network to accelerate clinical validation and indication expansion.
  • Commercialization Front: Leveraging the advanced manufacturing capabilities and regional policy benefits of the China Gene Valley to ensure efficient project implementation and facilitate market access.
This strategic partnership is a crucial step in the Group's pursuit of its vision "To Be the Global Leader in Regenerative Medicine, Redefining How Science Restores and Extends Human Life" Moving forward, the Group will continue to deepen collaborations with national scientific institutions and local governments, driving the translation of more cutting-edge research into clinical and market value. This will further consolidate and enhance its comprehensive competitiveness and leadership in regenerative medicine.
Hashtag: #Uni-BioScience

The issuer is solely responsible for the content of this announcement.

About Uni-Bio Science:

Uni-Bio Science Group Limited is an innovative biopharmaceutical enterprise listed on the Main Board of The Stock Exchange of Hong Kong Limited in 2001(Stock Code: 00690.HK). The Group is committed to powering the advancement of regenerative medicine with next-generation synthetic biology and complex peptide innovation. Focusing on four core research areas—muscular-skeletal regeneration, skin regeneration, ocular regeneration, and ENT regeneration—the Group has built a diversified product pipeline encompassing innovative biologics, high-value generic drugs, and medical aesthetics. The Group operates GMP-compliant production bases in Beijing, Dongguan, and Shenzhen, with fully integrated capabilities spanning R&D, manufacturing, and commercial sales. Uni-Bio Science Group is dedicated to becoming a global leader in regenerative medicine, redefining how science restores and extends human life.

About the National Engineering Research Center for Cell Growth Factor Drugs and Protein Formulations of Wenzhou Medical University:

The WMU NERC is an independent legal entity established by Wenzhou Medical University based on the national-level platform, the National Engineering Research Center for Cell Growth Factor Drugs and Protein Preparations. It undertakes downstream functions including engineering technology research and development, transformation of scientific and technological achievements, and technical services. Under the leadership of Chinese Academy of Engineering Academician Li Xiaokun, the Center has long been engaged in foundational research and novel drug discovery for cell growth factor drugs, holding a globally leading position. It brings together top-tier scientific teams, undertakes major national science and technology projects, and has successfully developed a series of innovative FGF drugs with independent intellectual property rights. Through synergistic collaboration with the National Key Laboratory for Macromolecular Drugs and Large‑Scale Preparation, the Center forms a complete innovation chain from source discovery and key technological breakthroughs to industrial translation. As the important R&D engine of the China Gene Valley, it continuously promotes the incubation and translation of several original new drug candidates, including a long-acting FGF21 variant.

About the People's Government of Ouhai District, Wenzhou:
The People's Government of Ouhai District, Wenzhou, is a key facilitator and supporter of this strategic cooperation, committed to building a first-class biomedical industry ecosystem. Its core platform, the "China Gene Valley," will provide comprehensive spatial support and specialized policy assistance for the cooperative projects across all stages – from R&D and pilot-scale testing to industrialization. Through specialized industrial policies, "full-cycle escort" services, and clinical resource coordination, Ouhai District empowers the implementation and growth of innovation projects, serving as a vital driver for regional biomedical industry innovation and development.

News from Asia

The Hoffman Agency Taps Darren Burns as Asia Pacific President

Appointment builds on the independent consultancy's global ambitionsSILICON VALLEY, USA – Media OutReach Newswire – 17 November 2026 – The Hoffman Agency, an independent global communications cons...

KFC Thailand Breaks Creative Boundaries in 2026 with Bold Campaigns and Its First-Ever Original Manga "Dumb Luck"

Turning Cultural Insights, Pop Culture and Everyday Moments into Unexpected and Unforgettable Brand ExperiencesBANGKOK, THAILAND – Media OutReach Newswire – 17 November 2026 – KFC Thailand has bee...

From Black Friday to Christmas: Garvee Unveils a Holiday Gift Guide for the Year-End Shopping Season

ONTARIO, CANADA – Media OutReach Newswire – 17 November 2026 – With Black Friday, Cyber Monday and Christmas just around the corner, it's time to start thinking about gifts for family, friends and...

CHAGEE Grows to Eight Asia Pacific Markets with Brunei Entry; Unveils New Rooted in Tea Store Design

In the new design, tea is not just what CHAGEE serves, but what shapes the spaceSINGAPORE – Media OutReach Newswire – 17 November 2026 – CHAGEE is growing its family in Asia Pacific, opening its f...

Century-Old Guizhou Time-Honored Brand "Laishigang Sauce-Aroma Baijiu" Establishes Foothold in Hong Kong to Launch Southeast Asian and International Expansion Strategy

HONG KONG SAR – Media OutReach Newswire – 17 November 2026 – Guizhou Laishigang Liquor Co., Ltd. ("Laishigang Liquor"), a fifth-generation, century-old sauce-aroma baijiu producer certified as a ...

THE WORLD ENDS 2026 Connects Asia’s Creative and Design Networks to Unlock New Business Opportunities

International design platform brings together creative talent, industry partners and regional business networks, targeting 200 buyer–seller connections to foster business collaboration and cross-bo...

Ayara Kamala Reveals a Refreshed Vision for Wellness in Phuket

BANGKOK, THAILAND – Media OutReach Newswire – 17 November 2026 - Ayara Kamala Resort & Spa, an intimate haven nestled along Phuket's prestigious Kamala coastline, has officially unveiled its r...

China-Indonesia Cultural Industry Exchange Symposium Held in Jakarta

JAKARTA, INDONESIA – Media OutReach Newswire – 17 November 2026 – On the afternoon of November 13, the China-Indonesia Cultural Industry Exchange Symposium, co-hosted by the China Intercontinental...

Disney and Visa Announce Multi-Year Strategic Alliance Across Asia Pacific

The alliance spans Disney-branded card programmes, cardholder benefits and joint marketing initiatives across the regionHONG KONG SAR – Media OutReach Newswire – 17 November 2026 – The Walt Disney...

Galaxy Resort Presents: "Plácido Domingo & José Carreras: The Legends United Opera Gala"

Greater China and Macau's Only Performance Galaxy Rewards select members can enjoy privileged priority booking from 10 December 2026.Tickets go on public sale from 14 December 2026 CaptionMACAU SAR...

Why the secrecy around car insurance?

Every year, millions of Australians receive their car insurance renewal and promise themselves they’ll look at it properly later. Then life gets in ...

Australian workers spend almost an hour a day administering email

Research finds email filing, searching and rework consuming an estimated 58 minutes a day and potentially exposing organisations to millionsAustralian...

Customer Service Is Becoming Part of the Small Business Sales and Marketing Engine

For Customer Service Week, 5-9 October, Thryv is urging small businesses to look beyond generating  enquiries and examine what happens after a custome...

Gift Cards as the gateway to agentic payments

Prepaid and stored value gives consumers the trust and control to try AI shopping agents By Blackhawk Network VP Head of ANZ Kieran Nolan For deca...

Why Data Accumulation Without Governance Undermines Sustainability Goals

In July 2026, Group 2 entities, the second cohort of Australian businesses, began their first reporting period under the mandatory climate disclosur...

Permanent $20,000 Instant Asset Write-Off Gives Small Businesses Greater Planning Certainty

The Federal Government’s decision to permanently legislate the $20,000 instant asset write-off will give eligible small businesses greater certainty...